DE60037597D1 - Imidazol- Derivate - Google Patents

Imidazol- Derivate

Info

Publication number
DE60037597D1
DE60037597D1 DE60037597T DE60037597T DE60037597D1 DE 60037597 D1 DE60037597 D1 DE 60037597D1 DE 60037597 T DE60037597 T DE 60037597T DE 60037597 T DE60037597 T DE 60037597T DE 60037597 D1 DE60037597 D1 DE 60037597D1
Authority
DE
Germany
Prior art keywords
imidazole derivatives
occurred
excessive
inappropriate
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60037597T
Other languages
English (en)
Other versions
DE60037597T2 (de
Inventor
Jerry L Adams
Neil W Johnson
Jeffrey H Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60037597D1 publication Critical patent/DE60037597D1/de
Application granted granted Critical
Publication of DE60037597T2 publication Critical patent/DE60037597T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
DE60037597T 1999-11-22 2000-11-20 Imidazol- Derivate Expired - Fee Related DE60037597T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US16688699P 1999-11-22 1999-11-22
US16681499P 1999-11-22 1999-11-22
US16689599P 1999-11-22 1999-11-22
US16688599P 1999-11-22 1999-11-22
US166886P 1999-11-22
US166814P 1999-11-22
US166895P 1999-11-22
US166885P 1999-11-22
PCT/US2000/031791 WO2001037835A1 (en) 1999-11-22 2000-11-20 Novel compounds

Publications (2)

Publication Number Publication Date
DE60037597D1 true DE60037597D1 (de) 2008-02-07
DE60037597T2 DE60037597T2 (de) 2008-12-11

Family

ID=27496721

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60037597T Expired - Fee Related DE60037597T2 (de) 1999-11-22 2000-11-20 Imidazol- Derivate
DE60015594T Expired - Fee Related DE60015594T2 (de) 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60015594T Expired - Fee Related DE60015594T2 (de) 1999-11-22 2000-11-20 Imidazolderivate und deren verwendung als raf kinase inhibitoren

Country Status (21)

Country Link
US (3) US7026336B1 (de)
EP (2) EP1232153B1 (de)
JP (2) JP2003514906A (de)
KR (1) KR20020050294A (de)
CN (1) CN1543346A (de)
AT (2) ATE382044T1 (de)
AU (2) AU1623601A (de)
BR (1) BR0015532A (de)
CA (1) CA2395564A1 (de)
CZ (1) CZ20021746A3 (de)
DE (2) DE60037597T2 (de)
ES (2) ES2228629T3 (de)
HK (1) HK1050190A1 (de)
HU (1) HUP0203403A3 (de)
IL (2) IL149150A0 (de)
MX (1) MXPA02005106A (de)
NO (1) NO20022318D0 (de)
NZ (1) NZ518032A (de)
PL (1) PL355912A1 (de)
TR (1) TR200201364T2 (de)
WO (2) WO2001037835A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
JP2003514906A (ja) 1999-11-22 2003-04-22 スミスクライン ビーチャム パブリック リミテッド カンパニー イミダゾール誘導体およびｒａｆキナーゼ阻害剤としてのその使用
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
AU2002236476A1 (en) 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) * 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
JP2006508051A (ja) 2002-08-29 2006-03-09 サイオス インク． 骨形成を促進する方法
EP2426122A1 (de) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylenharnstoffderivate als Inhibitoren von RAF Kinase
US7589112B2 (en) * 2002-10-24 2009-09-15 Merck Patent Gmbh Methylene urea derivatives
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP1670780A4 (de) * 2003-10-02 2008-12-17 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1727800A1 (de) * 2004-02-26 2006-12-06 MERCK PATENT GmbH Semicarbazidderivate als kinaseinhibitoren
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
WO2007016286A1 (en) * 2005-07-28 2007-02-08 Janssen Pharmaceutica N.V. Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CN101490046A (zh) 2006-05-09 2009-07-22 辉瑞产品公司 环烷基氨基酸衍生物及其药物组合物
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
CA2718936A1 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2485593B1 (de) * 2009-10-08 2015-01-07 GlaxoSmithKline LLC Kombination
PT3560498T (pt) 2009-10-16 2022-11-03 Novartis Ag Combinação que compreende um inibidor de mek e um inibidor de b-raf
EP2516668B1 (de) * 2009-12-22 2016-04-06 Csir Hemmung der aktivität von kinase- und synthetaseenzymen
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10605785B2 (en) * 2017-06-07 2020-03-31 General Electric Company Sensor system and method

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4447413A (en) * 1980-05-08 1984-05-08 Aviation Chemical, Inc. Drift influencing composition
US4348404A (en) 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
CA1175431A (en) 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US5166214A (en) 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
EP0653421B1 (de) 1993-11-12 1997-01-15 Ishihara Sangyo Kaisha Ltd. Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0889887A4 (de) 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
ATE271385T1 (de) 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
CN100443481C (zh) 1997-06-12 2008-12-17 艾文蒂斯药品有限公司 咪唑基-环缩醛类
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
CA2295021A1 (en) 1997-06-30 1999-01-28 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
WO1999021555A2 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
TR200100918T2 (tr) * 1997-12-22 2001-06-21 Bayer Corporation Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
IL136690A0 (en) * 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
PL344330A1 (en) * 1998-05-22 2001-10-22 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
WO2000001688A1 (fr) 1998-07-02 2000-01-13 Sankyo Company, Limited Composes heteroaryle a cinq elements
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AU6476599A (en) 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
AU4556800A (en) 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
JP2003514906A (ja) 1999-11-22 2003-04-22 スミスクライン ビーチャム パブリック リミテッド カンパニー イミダゾール誘導体およびｒａｆキナーゼ阻害剤としてのその使用
EP1263753B1 (de) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2002024680A1 (en) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
AU2002236476A1 (en) 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
WO2003022837A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors

Also Published As

Publication number Publication date
CA2395564A1 (en) 2001-05-31
TR200201364T2 (tr) 2002-10-21
US7026336B1 (en) 2006-04-11
NO20022318L (no) 2002-05-15
CN1543346A (zh) 2004-11-03
AU1623601A (en) 2001-06-04
DE60015594T2 (de) 2005-10-27
MXPA02005106A (es) 2002-11-07
ES2228629T3 (es) 2005-04-16
US7189745B1 (en) 2007-03-13
HK1050190A1 (zh) 2003-06-13
AU1529901A (en) 2001-06-04
EP1232153A2 (de) 2002-08-21
WO2001038324A3 (en) 2002-05-10
CZ20021746A3 (cs) 2002-10-16
JP2003514860A (ja) 2003-04-22
KR20020050294A (ko) 2002-06-26
US20070010534A1 (en) 2007-01-11
EP1233769A4 (de) 2004-12-29
WO2001037835A1 (en) 2001-05-31
EP1233769B1 (de) 2007-12-26
IL149150A0 (en) 2002-12-01
ATE281451T1 (de) 2004-11-15
WO2001038324A2 (en) 2001-05-31
PL355912A1 (en) 2004-05-31
HUP0203403A2 (hu) 2003-02-28
BR0015532A (pt) 2002-06-25
ATE382044T1 (de) 2008-01-15
DE60037597T2 (de) 2008-12-11
HUP0203403A3 (en) 2004-01-28
EP1232153B1 (de) 2004-11-03
NZ518032A (en) 2004-02-27
JP2003514906A (ja) 2003-04-22
EP1233769A1 (de) 2002-08-28
ES2298165T3 (es) 2008-05-16
DE60015594D1 (de) 2004-12-09
NO20022318D0 (no) 2002-05-15
IL149150A (en) 2007-02-11

Similar Documents

Publication Publication Date Title
DE60037597D1 (de) Imidazol- Derivate
DE60129154D1 (de) Neuartige verbindungen
ATE301651T1 (de) Substituierte benzimidazole
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
JO2503B1 (en) Benzathiazole derivatives
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
NZ513096A (en) Compositions for treating inflammatory response
ES2184097T3 (es) Nuevos compuestos.
TR199500956A2 (tr) Benzimidazol türevleri.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
CO5180558A1 (es) Derivados de n-[3-((piperidin-1-il)metil)-4-(fenil o hetero- ciclil)ciclopent-1-il]]amina utiles como moduladores de actividad del receptor de la quimioquina
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
PL356931A1 (en) Use of natural compounds having antiangiogenic activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee